한글목차

세계의 주사용 세포독성약물 시장은 2024년 131억 2,000만 달러에 달했고, 2032년까지 205억 9,000만 달러에 이를 것으로 예측되며, 예측 기간(2025-2033년) 중 CAGR은 5.2%를 나타낼 것으로 예측됩니다.

주사용 세포독성약은 성장하는 암세포를 사멸시키기 위해 화학요법에서 자주 사용되는 약입니다. 이 약은 특정 표적을 갖지 않으며 빠르게 성장하는 세포를 사멸시킴으로써 작용합니다. 이러한 약물은 세포 분열과 복제 단계를 억제하고 세포의 DNA 합성, RNA 전사, 단백질 생산, 미세 소관 구조 손상 등을 방해합니다. 주사용 세포독성제는 다양한 유형이 있으며, 알킬화제, 대사 길항제, 미세소관 손상제, 세포독성 항생제, 백금 화합물, 토포이소머라제 억제제 등을 포함합니다.

시장 역학:

촉진요인과 억제요인

암 이환율과 유병률 상승

주사용 세포 독성 약물은 다양한 암의 화학 요법에 널리 사용됩니다. 고령화, 라이프스타일의 변화, 환경요인 등 다양한 위험요인에 의해 세계적으로 암의 이환율과 유병률이 상승하고 있습니다. 암 이환율이 증가함에 따라 주사용 세포독성약을 이용한 화학요법 수요는 향후 증가할 것으로 예상됩니다. 예를 들어 국제암 연구기관의 예측에 따르면 2022년에는 2,000만명의 암 환자가 보고되었습니다. 2030년의 이환수는 2,410만명, 2040년에는 2,990만명으로 증가할 것으로 예측되고 있습니다.

게다가 신규 면역요법이나 표적요법의 등장에 의해 암 치료의 정세는 최근 극적으로 변화하고 있습니다. 시장 견인력은 높지만, 화학요법제와의 병용으로 처방되는 경우가 많습니다. 이것은 암 치료에서 세포 독성 약물의 중요한 역할을 반영합니다.

세포 독성 약물과 관련된 부작용은 시장 성장을 억제할 수 있습니다.

주사용 세포독성 약물은 특정 세포를 표적으로 하지 않고 신체에서 빠르게 성장하는 세포를 표적으로 합니다. 이들 세포는 신생물과는 별도로 정상적인 건강 세포를 포함할 수 있습니다. 그 결과, 치료받은 환자는 메스꺼움, 구토, 탈모, 주사 부위의 조직 손상, 골수 억제 등의 부작용을 경험할 수 있습니다. 장기적인 부작용으로는 심독성, 신경독성, 폐부전, 신부전 등이 있으며, 이는 환자에게 치명적입니다. 이러한 많은 부작용은 환자의 QOL에 큰 영향을 미쳐 미래의 채용에도 큰 지장을 초래할 가능성이 있습니다.

목차

제1장 조사 방법과 조사 범위

제2장 정의와 개요

제3장 주요 요약

제4장 시장 역학

• 영향요인
  • 성장 촉진요인
    • 암 발생률과 이환율 상승
    • 신제품 승인 증가
  • 억제요인
    • 세포독성약에 수반하는 부작용
  • 기회
  • 영향 분석

제5장 산업 분석

• Porter's Five Forces 분석
• 역학
• 가격 분석
• 파이프라인 분석
• 특허 분석
• 규제 분석

제6장 약제 클래스별

• 알킬화제
  • 시클로포스파미드
  • 이호스파미드
  • 부술팬
  • 기타
• 대사 길항제
  • 메토트렉세이트
  • 5-플루오로우라실
  • 기타
• 미소관 손상제
  • 빈크리스틴
  • 빈블라스틴
  • 파클리탁셀
  • 도세탁셀
  • 기타
• 세포독성 항생제
  • 독소루비신
  • 악티노마이신 D
  • 다우노르비신
  • 기타
• 백금 화합물
  • 시스플라틴
  • 카르보플라틴
  • 기타
• 토포이소머라제 억제제
• 기타

제7장 용도별

• 백혈병
• 림프종
• 유방암
• 폐암
• 난소암
• 대장암
• 췌장암
• 자가면역질환
• 기타

제8장 지역별

• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 독일
  • 영국
  • 프랑스
  • 스페인
  • 이탈리아
  • 기타 유럽
• 남미
  • 브라질
  • 아르헨티나
  • 기타 남미
• 아시아태평양
  • 중국
  • 인도
  • 일본
  • 한국
  • 기타 아시아태평양
• 중동 및 아프리카

제9장 경쟁 구도

• 경쟁 시나리오
• 시황·점유율 분석
• M&A 분석

제10장 기업 프로파일

• Pfizer Inc.
  • 기업 개요
  • 제품 포트폴리오
    • 제품 설명
    • 제품의 주요 실적 평가 지표(KPI)
    • 과거 및 예측의 제품 판매
    • 제품 판매량
  • 재무 개요
    • 회사 수익
    • 지역별 수익분배
    • 수익 예측
  • 주요 발전
    • 합병과 인수
    • 주요 제품 개발 활동
    • 규제 당국의 승인 등
  • SWOT 분석
• Bristol-Myers Squibb Company.
• Sandoz Group AG
• Fresenius Kabi AG
• Teva Pharmaceuticals USA, Inc.
• Viatris Inc.
• Amneal Pharmaceuticals LLC.
• Sun Pharmaceutical Industries Ltd.
• AdvaCare Pharma
• Sanofi
• 각 시장 진출기업에 대해서도 유사한 데이터가 제공됩니다.

제11장 부록

영문목차

The global Injectable cytotoxic drugs market reached US$ 13.12 billion in 2024 and is expected to reach US$ 20.59 billion by 2032, growing at a CAGR of 5.2% during the forecast period 2025-2033.

Injectable cytotoxic drugs are the medication often used in chemotherapy to kill the growing cancerous cells. These drugs have no specific targets and act by killing the fast-growing cells. They interfere in the cell division and replication stages and disrupt cellular DNA synthesis, RNA transcription, protein production, microtubule structural damage, etc. There are various classes of injectable cytotoxic drugs, which include alkylating agents, antimetabolites, microtubule damaging agents, cytotoxic antibiotics, platinum compounds, topoisomerase inhibitors, etc.

Market Dynamics: Drivers & Restraints

The rising incidence and prevalence of cancer

Injectable cytotoxic drugs are widely used in the chemotherapy of various cancers. Globally the incidence and prevalence of cancer are rising, due to various risk factors such as the aging population, lifestyle changes, environmental factors, etc. As cancer incidence grows, the demand for chemotherapy with injectable cytotoxic drugs is anticipated to increase in the future. For instance, as per the International Agency for Research on Cancer projections, in 2022, 20 million cancer cases were reported. The incidence cases in 2030 are expected to rise to 24.1 million in 2030 and 29.9 million in 2040.

Moreover, the cancer treatment landscape has drastically changed in recent years due to the launch of novel immunotherapies and targeted therapies. Although their market traction is high, they are often prescribed in combination with chemotherapeutic agents. This reflects the important role of cytotoxic drugs in cancer treatment.

Adverse effects associated with cytotoxic drugs may restrain the market growth.

Injectable cytotoxic drugs do not have a specific cell target, they target rapidly growing cells inside the body. These can also include normal healthy cells apart from neoplasms. As a result, the treated patient may experience adverse effects such as nausea, vomiting, hair loss, tissue damage at the site of injection, and bone marrow suppression. The long-term adverse effects include cardiotoxicity, neurotoxicity, lung failure, kidney failure, etc. which are fatal to the patient. This plethora of adverse effects can significantly affect the patient's quality of life, and can drastically hinder their adoption in the future.

Segment Analysis

The global injectable cytotoxic drugs market is segmented based on drug class, application, and region.

Platinum compounds in the drug class segment are expected to grow with the highest CAGR in the forecast period.

Platinum compounds are a class of cytotoxic agents that find their major application in cancer chemotherapy. These include drugs like cisplatin, carboplatin, and oxaliplatin which act by inhibiting the DNA synthesis and by cross-linking the DNA strands. These platinum compounds are efficacious in malignant cancers like breast, ovarian, lung, testicular, bladder, and colorectal cancers. Among the platinum compounds, cisplatin was the first approved drug, however, due to its adverse effects newer agents such as carboplatin and oxaliplatin were introduced into the market, which have significantly less adverse effect profile, and offer therapeutic beneficence.

These drugs are often used in combination with targeted therapies, immunotherapies, and other chemotherapeutic agents. Platinum compounds are also capable of treating certain cancers when prescribed as monotherapy. These drugs are also used in pediatric cases, and they drastically improve the survival rate. For instance, in April 2024, an article published in the American Journal of Clinical Oncology stated that platinum compounds increased survival rates in children with solid tumors such as osteosarcoma, neuroblastoma, retinoblastoma, germ cell tumors, etc.

As the incidence of these cancers rises, the adoption of platinum compounds is expected to significantly rise in the forecast period.

Geographical Analysis

North America is expected to hold a significant share of the Injectable cytotoxic drugs market.

North America region dominates the market due to its advanced healthcare infrastructure combined with the significant burden of cancer cases. For instance, as per the International Agency for Research on Cancer statistics, more than 2.6 million new cancer cases were reported in the North America region in 2022. Moreover, 3.1 million new cases in 2030, and 3.6 million new cases in 2040 are expected to be reported in the region. This rising burden of disease is expected to significantly raise the demand for cytotoxic drugs in the future.

Additionally, due to high awareness among the patient population in the region, they are diagnosed at early stages and receive cancer chemotherapy at the earliest. This reflects the higher treatment rates among cancer patients, as compared to other high-income countries.

In addition, the region has a strong presence of market players such as Pfizer, Bristol Myers Squibb Company, Viatris, Teva, Sandoz, etc. who generate higher revenue from sales of their products. For Instance, one of the most commonly used injectable cytotoxic drugs i.e., paclitaxel sold under the brand name ABRAXANE, manufactured by Bristol-Myers Squibb Company has generated a sales value of US$ 1 billion in 2023. Among this US$ 1 billion, ~ 70% is generated from the U.S. market.

Competitive Landscape

The major global players in the Injectable cytotoxic drugs market are Pfizer Inc., Bristol-Myers Squibb Company., Sandoz Group AG, Fresenius Kabi AG, Teva Pharmaceuticals USA, Inc., Viatris Inc., Amneal Pharmaceuticals LLC., Sun Pharmaceutical Industries Ltd., AdvaCare Pharma, and Sanofi among others.

Key Developments

• In October 2024, Sandoz launched a generic paclitaxel formulation in the U.S. market which has become the first generic version of its Abraxane approved by the U.S. FDA. The drug is available in injectable suspension (albumin-bound) and is indicated for metastatic breast cancer patients.
• In August 2024, Lupin Limited launched Doxorubicin Hydrochloride liposome injection single-dose vials in the U.S. market. The launch is based on ANDA approval from the U.S. FDA provided to ForDoz Pharma Corporation, an alliance partner of Lupin in the U.S.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming pharmaceutical advancements.
• Drug Class Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient Drug Class delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global Injectable cytotoxic drugs market report would provide approximately 54 tables, 52 figures, and 165 pages.

Drug Class Audience 2023

• Manufacturers: Pharmaceutical, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Drug Class
• 3.2. Snippet by Application
• 3.3. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Rising Incidence and Prevalence of Cancers
    • 4.1.1.2. Rising New Product Approvals
  • 4.1.2. Restraints
    • 4.1.2.1. Adverse Effects Associated with Cytotoxic Drugs
  • 4.1.3. Opportunities
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Epidemiology
• 5.3. Pricing Analysis
• 5.4. Pipeline Analysis
• 5.5. Patent Analysis
• 5.6. Regulatory Analysis

6. By Drug Class

• 6.1. Introduction
  • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 6.1.2. Market Attractiveness Index, By Drug Class
• 6.2. Alkylating Agents*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.2.3. Cyclophosphamide
  • 6.2.4. Ifosfamide
  • 6.2.5. Busulfan
  • 6.2.6. Others
• 6.3. Antimetabolites
  • 6.3.1. Methotrexate
  • 6.3.2. 5-Fluorouracil
  • 6.3.3. Others
• 6.4. Microtubule Damaging Agents
  • 6.4.1. Vincristine
  • 6.4.2. Vinblastine
  • 6.4.3. Paclitaxel
  • 6.4.4. Docetaxel
  • 6.4.5. Others
• 6.5. Cytotoxic Antibiotics
  • 6.5.1. Doxorubicin
  • 6.5.2. Actinomycin D
  • 6.5.3. Daunorubicin
  • 6.5.4. Others
• 6.6. Platinum Compounds
  • 6.6.1. Cisplatin
  • 6.6.2. Carboplatin
  • 6.6.3. Others
• 6.7. Topoisomerase Inhibitors
• 6.8. Others

7. By Application

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 7.1.2. Market Attractiveness Index, By Application
• 7.2. Leukemia*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Lymphoma
• 7.4. Breast Cancer
• 7.5. Lung Cancer
• 7.6. Ovarian Cancer
• 7.7. Colorectal Cancer
• 7.8. Pancreatic Cancer
• 7.9. Autoimmune Conditions
• 7.10. Others

8. By Region

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 8.1.2. Market Attractiveness Index, By Region
• 8.2. North America
  • 8.2.1. Introduction
  • 8.2.2. Key Region-Specific Dynamics
  • 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.2.5.1. U.S.
    • 8.2.5.2. Canada
    • 8.2.5.3. Mexico
• 8.3. Europe
  • 8.3.1. Introduction
  • 8.3.2. Key Region-Specific Dynamics
  • 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.3.5.1. Germany
    • 8.3.5.2. U.K.
    • 8.3.5.3. France
    • 8.3.5.4. Spain
    • 8.3.5.5. Italy
    • 8.3.5.6. Rest of Europe
• 8.4. South America
  • 8.4.1. Introduction
  • 8.4.2. Key Region-Specific Dynamics
  • 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.4.5.1. Brazil
    • 8.4.5.2. Argentina
    • 8.4.5.3. Rest of South America
• 8.5. Asia-Pacific
  • 8.5.1. Introduction
  • 8.5.2. Key Region-Specific Dynamics
  • 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.5.5.1. China
    • 8.5.5.2. India
    • 8.5.5.3. Japan
    • 8.5.5.4. South Korea
    • 8.5.5.5. Rest of Asia-Pacific
• 8.6. Middle East and Africa
  • 8.6.1. Introduction
  • 8.6.2. Key Region-Specific Dynamics
  • 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

9. Competitive Landscape

• 9.1. Competitive Scenario
• 9.2. Market Positioning/Share Analysis
• 9.3. Mergers and Acquisitions Analysis

10. Company Profiles

Key Market Players

• 10.1. Pfizer Inc.*
  • 10.1.1. Company Overview
  • 10.1.2. Product Portfolio
    • 10.1.2.1. Product Description
    • 10.1.2.2. Product Key Performance Indicators (KPIs)
    • 10.1.2.3. Historic and Forecasted Product Sales
    • 10.1.2.4. Product Sales Volume
  • 10.1.3. Financial Overview
    • 10.1.3.1. Company Revenue's
    • 10.1.3.2. Geographical Revenue Shares
    • 10.1.3.3. Revenue Forecasts
  • 10.1.4. Key Developments
    • 10.1.4.1. Mergers & Acquisitions
    • 10.1.4.2. Key Product Development Activities
    • 10.1.4.3. Regulatory Approvals etc.
  • 10.1.5. SWOT Analysis
• 10.2. Bristol-Myers Squibb Company.
• 10.3. Sandoz Group AG
• 10.4. Fresenius Kabi AG
• 10.5. Teva Pharmaceuticals USA, Inc.
• 10.6. Viatris Inc.
• 10.7. Amneal Pharmaceuticals LLC.
• 10.8. Sun Pharmaceutical Industries Ltd.
• 10.9. AdvaCare Pharma
• 10.10. Sanofi
• Similar data will be provided for each market player.

LIST NOT EXHAUSTIVE

11. Appendix

• 11.1. About Us and Services
• 11.2. Contact Us